Piraye Yurttas Beim, PhD is the founder and CEO of Celmatix, a preclinical-stage biotech transforming women’s lives through better ovarian health.

Founded in 2009 as one of the first FemTech companies, Celmatix’s mission is to accelerate precision medicine in women’s health. Under Dr. Beim’s leadership, Celmatix has been recognized as one of Fast Company’s Most Innovative Companies, pioneering breakthroughs in decoding the genomic drivers of ovarian function and unlocking unprecedented insight into unique aspects of female biology and health. Dr. Beim’s publications have been widely cited, and she has been a primary inventor of many of Celmatix’s innovations, including groundbreaking drug programs for improving and extending ovarian function.

Dr. Beim has dedicated herself to innovating in women’s health for more than 20 years. During her PhD work at Cornell University (Weill, NYC) and Memorial Sloan Kettering Cancer Center, she was on the front lines of the precision medicine revolution in oncology. She then completed her post-doc at the University of Cambridge (UK), focusing on the science of fertility.

Dr. Beim is also widely recognized as a business leader and entrepreneur. She is a member of the Aspen Global Leadership Network, was named to Elle Magazine’s “Women in Tech” Power List, Crain’s 40 Under 40 and its Notable Women in Tech, Goldman Sachs’s Most Intriguing Entrepreneurs, Top 15 founders disrupting their industries by Fortune, and Rock Health’s Disruptive Founder of the Year. She is also on the board of the Endometriosis Foundation of America and the Center on Rural Innovation.